Connect Sign In
ARUP presented key molecular pathology advancements at AMP 2024 on topics such as viral load prediction, automated DNA extraction, and parasite detection.
This edition features interviews with company leaders describing ARUP’s approaches to comply with the FDA’s rule and a video about how ARUP helped a family on a rare disease diagnostic journey.
ARUP Laboratories is partnering with Augurex Life Sciences Corp. to include the 14-3-3η test in the ARUP test menu to enhance the early detection of rheumatoid arthritis.
A new ARUP Consult® topic on testing for preeclampsia, which can be difficult to diagnose, distills guidelines from several sources to help clinicians order the right test at the right time.
A new, first-of-its-kind test uses blood-based biomarkers to assess the risk of developing preeclampsia with severe features and facilitates appropriate interventions.
The lone star tick, which can transmit infectious diseases and trigger a serious red meat allergy, is spreading into new areas. ARUP Consult offers guidance to help diagnose tickborne illnesses.
The ARUP Consult® Fragile X (FMR1)-Associated Disorders topic offers information for providers from numerous medical specialties because of the variety of conditions associated with the FMR1 gene.
The ARUP Consult Laboratory Testing for Developmental Delay, Intellectual Disability, and Autism Spectrum Disorder topic now includes exome and genome sequencing as a first- or second-tier test.
Join ARUP in kickstarting Lab Week with a curated selection of podcasts, articles, and lectures that emphasize the important role medical lab professionals play in improving and saving patient lives.
ARUP medical directors and experts will be present to discuss the latest developments in neurology laboratory testing at the upcoming American Academy of Neurology (AAN) Annual Meeting.
The MenoCheck test helps providers treat women who are experiencing menopausal transition and manage the health risks associated with decreased estrogen production.
ARUP’s new lupus anticoagulant panel neutralizes several interfering anticoagulants to limit their impact on test results and reduce the likelihood of false-negative and false-positive results.
